Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Novel VECTOR Procedure Creates Percutaneous Aorto-Coronary Bypass

Yael L. Maxwell

January 14, 2026

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

L.A. McKeown

August 23, 2023

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Caitlin E. Cox

March 04, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

Brachytherapy Remains an Option for DES In-Stent Restenosis

Yael L. Maxwell

January 12, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Opinion CV Team Dispatch

June 2022 News Roundup

L.A. McKeown

June 01, 2022

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

Todd Neale

September 17, 2021

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Conference News EuroPCR 2019

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

L.A. McKeown

June 06, 2019

Advertisement

Novel VECTOR Procedure Creates Percutaneous Aorto-Coronary Bypass

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Brachytherapy Remains an Option for DES In-Stent Restenosis

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

June 2022 News Roundup

Renal Denervation a Third Option for Hypertension, European Experts Say

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content